Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study

doi:10.3748/wjg.v28.i36.5351

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3820)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

159

WORD

HTML

1657

Figures (1-2)

311

Tables (1-4)

270

Sum=2435

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

325

Download

1060

Sum=1385

Sep 28, 2022 (publication date) through Aug 28, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Sep 28, 2022; 28(36): 5351-5363
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5351

Table 1 Baseline characteristics of the enrolled patients

	Patients without early EHR (n = 705)	Patients with early EHR (n = 74)	P value
Age (yr)	59.49 ± 10.08	56.51 ± 10.37	0.020
Male sex (n, %)	603 (85.5)	64 (86.5)	0.824
BMI (kg/m²)	23.89 ± 3.03	24.10 ± 2.98	0.790
Etiology of hepatitis, n (%)			0.569
HBV/HCV	425 (63.2)/55 (8.2)	53 (73.6)/8 (11.1)
Alcohol/combined	40 (10.4)/49 (7.0)	5 (6.9)/2 (2.8)
NASH/unknown	1 (0.1)/73 (10.8)	0/4 (5.6)
ALP (U/L)	89.25 ± 44.04	113.23 ± 106.76	0.059
Albumin (mg/dL)	4.36 ± 0.45	4.19 ± 0.48	0.002
ALBI grade ≥ 2, n (%)	97 (13.8)	16 (21.9)	0.063
ICG R15	12.02 ± 7.29	12.58 ± 7.62	0.566
Preoperative serum AFP > 400 (IU/mL)	127 (18.6)	24 (32.9)	0.004
Sum of tumor size	4.17 ± 2.44	6.06 ± 3.38	< 0.001
Tumor numbers	1.19 ± 0.54	1.32 ± 0.82	0.176
BCLC stage, n (%)			< 0.001
0/A/≥ B	89 (12.7)/491 (69.9)/122 (17.4)	3 (4.1)/44 (59.5)/27 (36.5)
Pathological mUICC stage, n (%)			< 0.001
I/II/≥ III	111 (15.8)/431 (61.4)/160 (22.8)	2 (2.7)/32 (43.2)/40 (54.1)
Radiological mUICC stage, n (%)			< 0.001
I/II/≥ III	112 (15.9%)/463 (66.0%)/127 (18.1%)	4 (5.4)/43 (58.1)/27 (36.5)
Beyond Milan criteria, n (%)	179 (25.4)	40 (54.1)	< 0.001
Macrovascular invasion, n (%)	32 (4.6)	11 (14.9)	< 0.001
Hospital stay, days (median, range)	13.3 ± 7.1	15.6 ± 75.6	0.049
Follow-up duration, years (median, range)	4.8 (0.23-15.36)	1.8 (0.31-1.43)	< 0.001

Values are presented as mean ± SD. SD: Standard deviation; EHR: Extrahepatic recurrence; BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine transaminase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; mUICC: Modified Union for International Cancer Control.

Table 2 Comparison of surgical findings and clinical outcomes in patients with and without extrahepatic recurrence

	Patients without early EHR (n = 705)	Patients with early EHR (n = 74)	P value
Margin involvement, n (%)	16 (2.3%)	4 (5.5%)	0.104
Metastatic lymph nodes, n (%)	1 (0.1)	3 (4.1)	< 0.001
Microvascular invasion, n (%)	114 (16.3)	33 (44.6)	< 0.001
Serosal invasion, n (%)	13 (1.9)	4 (5.4)	0.052
Bile duct invasion, n (%)	9 (1.3)	1 (1.4)	0.975
Capsule formation, n (%)	456 (66.7)	53 (71.6)	0.389
Multicentricity, n (%)	54 (7.8)	8 (10.8)	0.372
Satellite nodule, n (%)	84 (12.2)	17 (23.0)	0.009
Intrahepatic metastasis, n (%)	8 (1.2)	2 (2.7)	0.268
Necrosis, n (%)	286 (41.5)	61 (82.4)	< 0.001
Haemorrhage, n (%)	296 (43.0)	46 (62.2)	0.002
Fatty change, n (%)	246 (36.0)	15 (20.5)	0.008
Major Edmondson-Steiner grade, n (%)			0.243
1/2	30 (4.4)/352 (51.8)	2 (2.7)/30 (41.1)
3/4	274 (40.3)/24 (3.5)	38 (52.1)/3 (4.1)
Worst Edmondson-Steiner grade, n (%)			0.094
1/2	8 (1.1)/130 (18.9)	1 (1.4)/5 (6.8)
3/4	357 (51.8)/194 (28.2)	40 (54.1)/28 (37.8)
Serum AFP > 400 IU/mL on first recurrence	34 (10.2)	22 (31.0)	< 0.001
Recurrence-free survival, mo (median, range)	32.4 (2.24-177.34)	5.21 (2.04-20.28)	< 0.001
mUICC T stage on first recurrence, n (%)			< 0.001
0/1	6 (1.8)/144 (43.6)	10 (13.7)/23 (31.5)
2/3	131 (39.7)/39 (11.8)	14 (19.2)/20 (27.4)
4	10 (3.0)	6 (8.2)
Second treatment modality			0.070
Surgery/RFA	46 (6.5)/95 (13.5)	9 (12.2)/10 (13.5)
TACE/RFA + TACE	156(22.1)/14 (2.0)	13 (17.6)/6 (8.1)
RT/systemic chemotherapy/BSC	20 (2.8)/11 (1.5)/20 (2.8)	3 (4.1)/1 (1.4)

AFP: Alpha-fetoprotein; mUICC: Modified Union for International Cancer Control stage; RFA: Radiofrequency ablation; TACE: Trans-arterial chemoembolization; RT: Radiotherapy; BSC: Best supportive care.

Table 3 Univariate and multivariate analyses of factors associated with early extrahepatic recurrence

	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Serum albumin < 4.0 g/dL	2.27 (1.56-3.29)	< 0.001	2.19 (1.45-3.31)	< 0.001
Serum ALP > 100 U/L	1.76 (1.24-2.52)	0.002	1.59 (1.08-2.32)	0.018
ALBI grade ≥ 2	1.71 (1.12-2.59)	0.012
Surgical margin involvement	2.30 (1.07-4.93)	0.032	2.53 (1.09-5.90)	0.032
Pathological mUICC stage (III, IVa)	2.94 (2.09-4.12)	< 0.001
Multiple tumors¹	3.21 (1.57-6.56)	0.002
Venous/lymphatic involvement²	2.98 (2.09-4.25)	< 0.001	1.90 (1.28-2.83)	0.002
Serosa invasion	2.86 (1.33-6.12)	0.007
Bile duct invasion	3.25 (1.20-8.83)	0.020
Satellite nodule	2.69 (1.83-3.94)	< 0.001	1.73 (1.14-2.63)	0.011
Intrahepatic metastasis	2.99 (1.10-8.09)	0.032
Tumor necrosis	3.18 (2.20-4.61)	<0.001	1.92 (1.29-2.79)	0.001
Tumor hemorrhage	1.81 (1.28-2.55)	0.001
Sum of tumor size ≥ 7 cm	3.25 (2.23-4.73)	< 0.001	1.84 (1.21-2.77)	0.004
Macrovascular invasion	2.48 (1.37-4.50)	0.003	2.30 (1.24-4.26)	0.008
Serum AFP > 1500 IU/mL	1.99 (1.27-3.12)	0.003

¹Number of tumors examined during pathological evaluation.

²Confirmed findings during pathological evaluation.

HR: Hazards ratio; CI: Confidence interval; ALP: Alkaline phosphatase; ALBI: Albumin-bilirubin; mUICC: Modified Union for International Cancer Control; AFP: Alpha-fetoprotein.

Table 4 Univariate and multivariate analysis of factors associated with overall survival

	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Serum albumin < 4.0 g/dL	2.14 (1.61-2.85)	< 0.001	2.44 (1.79-3.32)	< 0.001
ALBI grade ≥ 2	1.84 (1.36-2.51)	< 0.001
Serum ALP > 100 U/L	1.84 (1.41-2.41)	< 0.001	1.62 (1.22-2.16)	0.001
Single tumor¹	1.87 (1.21-2.91)	0.005
Major Edmondson-Steiner grade ≥ 3	1.64 (1.26-2.13)	< 0.001	1.45 (1.10-1.90)	0.008
Venous/lymphatic involvement²	2.44 (1.84-3.22)	< 0.001
Pathological mUICC stage (III, IVa)	2.59 (2.00-3.35)	< 0.001	1.63 (1.21-2.22)	0.002
Bile duct invasion	2.72 (1.21-6.13)	0.016
Intrahepatic metastasis	3.66 (1.72-7.77)	0.001
Multicentricity	1.91 (1.29-2.82)	0.001
Satellite nodule	2.45 (1.82-3.30)	< 0.001	1.92 (1.38-2.69)	< 0.001
Tumor necrosis	2.12 (1.63-2.77)	< 0.001	1.35 (1.030-1.78)	0.030
Tumor hemorrhage	1.58 (1.21-2.05)	0.001
Sum of tumor size ≥ 7 cm	2.21 (1.63-3.00)	< 0.001
Beyond Milan criteria	1.79 (1.38-2.33)	< 0.001
Serum AFP > 1500 IU/mL	1.47 (1.01-2.15)	0.046
Early extrahepatic recurrence	7.72 (5.67-10.51)	< 0.001	6.77 (4.81-9.52)	< 0.001

¹Number of tumors examined during pathological evaluation.

²Confirmed findings during pathological evaluation.

HR: Hazards ratio; CI: Confidence interval; ALBI: Albumin-bilirubin; ALP: Alkaline phosphatase; mUICC: Modified Union for International Cancer Control; AFP: Alpha-fetoprotein.

Citation: Yoon JH, Choi SK, Cho SB, Kim HJ, Ko YS, Jun CH. Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study. World J Gastroenterol 2022; 28(36): 5351-5363
URL: https://www.wjgnet.com/1007-9327/full/v28/i36/5351.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i36.5351